Britannia Life Sciences Inc. (CSE:BLAB)
Canada
· Delayed Price · Currency is CAD 0.100
-0.005 (-4.76%)
Mar 5, 2026, 1:14 PM EST
Britannia Life Sciences Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Revenue | -1 | 0.37 | 0.52 | 6.4 | 7.3 | 1.42 | Upgrade
|
| Revenue Growth (YoY) | - | -28.55% | -91.93% | -12.28% | 412.42% | - | Upgrade
|
| Cost of Revenue | -0.27 | 0.34 | 0.38 | 1.77 | 2.04 | 0.25 | Upgrade
|
| Gross Profit | -0.73 | 0.03 | 0.14 | 4.64 | 5.26 | 1.18 | Upgrade
|
| Selling, General & Admin | 1.84 | 2.24 | 1.46 | 2.59 | 2.54 | 0.79 | Upgrade
|
| Other Operating Expenses | - | - | - | - | - | 0.1 | Upgrade
|
| Operating Expenses | 1.81 | 2.24 | 1.69 | 3.64 | 3.65 | 0.89 | Upgrade
|
| Operating Income | -2.53 | -2.22 | -1.55 | 0.99 | 1.62 | 0.29 | Upgrade
|
| Interest Expense | - | -0.11 | -0.1 | -0.85 | -2.31 | -0.36 | Upgrade
|
| Earnings From Equity Investments | -3.01 | -2.09 | -0.96 | -0.02 | -0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 14.22 | -0.4 | -0.11 | -0.06 | 0.61 | 0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.15 | 0.06 | -3.82 | 4.41 | -3.22 | 0.29 | Upgrade
|
| EBT Excluding Unusual Items | 7.69 | -4.75 | -6.54 | 4.47 | -3.3 | 0.41 | Upgrade
|
| Impairment of Goodwill | - | - | -0.04 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.58 | 0.23 | 0.47 | 1.39 | - | - | Upgrade
|
| Other Unusual Items | -0.04 | -0.04 | - | - | -9.97 | -0.01 | Upgrade
|
| Pretax Income | 9.23 | -4.56 | -6.12 | 5.86 | -13.27 | 0.4 | Upgrade
|
| Income Tax Expense | 1.61 | - | - | 0.02 | 0.71 | 0.26 | Upgrade
|
| Earnings From Continuing Operations | 7.61 | -4.56 | -6.12 | 5.84 | -13.99 | 0.14 | Upgrade
|
| Earnings From Discontinued Operations | 12.77 | 12.07 | 1.72 | - | - | - | Upgrade
|
| Net Income to Company | 20.38 | 7.51 | -4.4 | 5.84 | -13.99 | 0.14 | Upgrade
|
| Minority Interest in Earnings | 0.11 | -0.11 | -0.37 | -0.75 | -1.47 | -0.3 | Upgrade
|
| Net Income | 20.49 | 7.39 | -4.77 | 5.08 | -15.46 | -0.16 | Upgrade
|
| Net Income to Common | 20.49 | 7.39 | -4.77 | 5.08 | -15.46 | -0.16 | Upgrade
|
| Shares Outstanding (Basic) | 162 | 162 | 162 | 162 | 110 | 78 | Upgrade
|
| Shares Outstanding (Diluted) | 162 | 162 | 162 | 162 | 110 | 78 | Upgrade
|
| Shares Change (YoY) | - | - | 0.07% | 48.07% | 41.06% | 1138.06% | Upgrade
|
| EPS (Basic) | 0.13 | 0.05 | -0.03 | 0.03 | -0.14 | -0.00 | Upgrade
|
| EPS (Diluted) | 0.13 | 0.05 | -0.03 | 0.03 | -0.14 | -0.00 | Upgrade
|
| Free Cash Flow | -4.09 | -2.62 | 2.09 | 1.95 | 2.71 | -0.54 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.02 | 0.01 | 0.01 | 0.03 | -0.01 | Upgrade
|
| Gross Margin | - | 7.40% | 26.65% | 72.43% | 72.08% | 82.64% | Upgrade
|
| Operating Margin | - | -599.98% | -299.60% | 15.52% | 22.13% | 20.23% | Upgrade
|
| Profit Margin | - | 2001.95% | -922.51% | 79.39% | -211.76% | -11.03% | Upgrade
|
| Free Cash Flow Margin | - | -709.38% | 404.71% | 30.50% | 37.16% | -38.15% | Upgrade
|
| EBITDA | -2.44 | -2.11 | -1.42 | 1.1 | 1.75 | 0.32 | Upgrade
|
| EBITDA Margin | - | - | -275.67% | 17.25% | 24.02% | 22.24% | Upgrade
|
| D&A For EBITDA | 0.09 | 0.1 | 0.12 | 0.11 | 0.14 | 0.03 | Upgrade
|
| EBIT | -2.53 | -2.22 | -1.55 | 0.99 | 1.62 | 0.29 | Upgrade
|
| EBIT Margin | - | - | -299.60% | 15.52% | 22.13% | 20.23% | Upgrade
|
| Effective Tax Rate | 17.48% | - | - | 0.34% | - | 64.31% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.